ZEVRA THERAPEUTICS INC. - COMMON STOCK

Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024

18 3月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

04 3月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate at Upcoming Investor Conferences

28 2月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 2月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors

23 1月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

08 1月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer

04 1月 2024 08:55:49 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

27 12月 2023 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

20 11月 2023 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results

07 11月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET

31 10月 2023 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October

19 10月 2023 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director

10 10月 2023 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting

05 10月 2023 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

02 10月 2023 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference

20 9月 2023 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

09 9月 2023 20:00:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

05 9月 2023 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

31 8月 2023 07:30:00 条件 Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results

14 8月 2023 07:30:00 条件 Nasdaq GlobeNewswire